Biden budget would cap monthly insulin prices at $35 for people with private insurance

Biden budget would cap monthly insulin prices at  for people with private insurance


A woman who had type 1 diabetes since she was a teenager, displays her insulin for injection, on March 02, 2023 in New York City.

Spencer Platt | Getty Images

President Joe Biden’s federal budget proposal would cap insulin prices at $35 per month for people with private insurance plans.

The Inflation Reduction Act capped monthly insulin costs at that price for seniors in January, but left out everyone who wasn’t on Medicare. Biden called on Congress in his State of the Union speech to finish the job and cap insulin at $35 a month for everybody.

Drugmaker Eli Lilly got ahead of a potential federal mandate, announcing earlier this month that it would cap insulin at $35 per month for people with private insurance at certain retail pharmacies. But CEO David Ricks, in a statement, said seven out of 10 Americans do not use Lilly’s insulin. He called on federal policymakers and employers to help make the costs of the injections more affordable.

Read more on Biden’s fiscal year 2024 budget plan:

Biden praised Lilly’s decision and called on other manufacturers to follow suit. He also reiterated his call for Congress to lower insulin prices for everyone else.

About 40% of people with diabetes have private insurance while 5% are not insured, according to the American Diabetes Association.

Some Republicans in Congress oppose to the move to cap insulin prices. Rep. Cathy Rodgers, who chairs the House Energy and Commerce Committee, called the Biden administration’s efforts to lower insulin prices as “socialist” and a “federal mandate” that is bad for market competition.

Join CNBC’s Healthy Returns on March 29th, where we’ll convene a virtual gathering of CEOs, scientists, investors and innovators in the health care space to reflect on the progress made today to reinvent the future of medicine. Plus, we’ll have an exclusive rundown of the best investment opportunities in biopharma, health-tech and managed care. Learn more and register today: 



Source

Healthy Returns: A key step forward for Novo Nordisk’s GLP-1 pill
Health

Healthy Returns: A key step forward for Novo Nordisk’s GLP-1 pill

Novo Nordisk flags flutter outside their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. Tom Little | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. A closely watched pill from […]

Read More
Why U.S. cattle ranchers say Trump’s Argentine beef import talk is no solution to domestic food supply threat
Health

Why U.S. cattle ranchers say Trump’s Argentine beef import talk is no solution to domestic food supply threat

Cattle detained in the pens of the Chihuahua Regional Livestock Union , at the Jeronimo-Santa Teresa border crossing in Ciudad Juarez, Mexico on November 27, 2024, after the United States stopped imports of Mexican cattle due to the presence of screwworm. Anadolu | Anadolu | Getty Images Cattle ranchers in Texas and around the country […]

Read More
Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost
Health

Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost

Dario Amodei, Anthropic CEO, speaking on CNBC’s Squawk Box outside the World Economic Forum in Davos, Switzerland on Jan. 21st, 2025. Gerry Miller | CNBC Anthropic on Monday announced Claude for Life Sciences, a new offering for researchers to use the company’s artificial intelligence technology in the advancement of scientific discovery.  Claude for Life Sciences is […]

Read More